Company News | Jacobio Pharma

97 press releases in total

2025

Aug 30, 2025

Jacobio Pharma Announces 2025 Interim Results

[More]
Jul 2, 2025

Jacobio Pharma Completes First Patient Dosage of Pan-KRAS Inhibitor in U.S.

[More]
May 22, 2025

Jacobio’s KRAS G12C Inhibitor Glecirasib Approved for Market Launch

[More]
May 9, 2025

SHP2 Inhibitor Sitneprotafib Combination Therapy Data Published in Academic Journal

[More]
Mar 20, 2025

Jacobio Pharma Announces 2024 Annual Results

[More]
Jan 7, 2025

The Registrational Clinical Data of Glecirasib was Published in Nature Medicine

[More]

2024

Dec 10, 2024

Jacobio Pharma Presented preliminary Data on BET Inhibitor for Myelofibrosis at 2024 ASH

[More]
Nov 25, 2024

Jacobio Pharma Completes First Patient Dosage of Pan-KRAS Inhibitor

[More]
Oct 21, 2024

Glecirasib Pancreatic Cancer Indication Received Orphan Drug Designation from EMA

[More]
Oct 9, 2024

Jacobio Presents Pre-clinical Data of SHP2 plus KRAS G12C

[More]
Oct 3, 2024

Jacobio Pharma to Present BET Inhibitor Data at 2024 ASH

[More]
Sep 27, 2024

Jacobio Received RMB 172 million Payment

[More]
Sep 26, 2024

Jacobio Pharma Received Pan-KRAS Inhibitor IND Approval from China CDE

[More]
Sep 20, 2024

Jacobio Pharma Received Pan-KRAS Inhibitor IND Approval from FDA

[More]
Sep 15, 2024

Jacobio Pharma Presents Efficacy Data of Glecirasib in Combination with JAB-3312 with PD-L1 Expression Levels

[More]
Aug 30, 2024

Jacobio Out-licensed KRAS G12C Inhibitor Glecirasib and SHP2 Inhibitor JAB-3312 to Allist in China

[More]
Aug 12, 2024

Jacobio’s SHP2 Inhibitor JAB-3312 Published in Journal of Medicinal Chemistry

[More]
Aug 7, 2024

Jacobio Completes First Patient Dosage in the Phase III Clinical Trial of JAB-3312 in Combination with Glecirasib

[More]
Jul 26, 2024

Jacobio Completes First Patient Dosage of p53 Y220C Activator

[More]
Jun 13, 2024

Jacobio Appoints Dr. Alan Xiao as Vice President of Clinical Pharmacology

[More]

Pages